SCHEMBL2215030

SCHEMBL2215030

CCNC(=O)c1ccc(C)c(-c2ccc(C(=O)c3ccc(F)cc3)c(Cl)n2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 7/20 0.42
BRD4 O60885 1/20 0.41
HTR7 P34969 1/20 0.40
CYP2C9 P11712 1/20 0.40
LMNA P02545 2/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
JAK2 O60674 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ABL1 P00519 2/20 0.38
PDK2 Q15119 1/20 0.36
PDE2A O00408 2/20 0.36
PDE10A Q9Y233 2/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2A Q12879 1/20 0.36
ROCK2 O75116 1/20 0.36
ROCK1 Q13464 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12512906 0.90 MAPK14 (0.41) MAPK14BRD4HTR7CYP2C9LMNA
SCHEMBL2216235 0.79 MAPK14 (0.43) MAPK14BRD4CYP2C9LMNAMAPT
SCHEMBL2217263 0.75 MAPK14 (0.44) MAPK14ABL1
SCHEMBL2215902 0.73 MAPK14 (0.55) MAPK14CYP2C9
SCHEMBL2217695 0.71 MAPK14 (0.49) MAPK14BRD4CYP2C9ROCK2ROCK1
SCHEMBL2216481 0.69 PARP1 (0.43) MAPK14BRD4CYP2C9MAPTABL1
SCHEMBL2215777 0.69 MAPK14 (0.41) MAPK14ABL1ROCK2ROCK1
SCHEMBL2216227 0.69 MAPT (0.42) MAPK14LMNATP53MAPTABL1
SCHEMBL2215356 0.69 ACHE (0.49) MAPK14LMNAMAPTKMT2AJAK2
SCHEMBL2215293 0.68 MAPK14 (0.44) MAPK14ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1709046-B1 P38 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-07-27 EP disclosed
US-20070161673-A1 P38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2007-07-12 US disclosed
US-20070161673-A1 P38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161673-A1 P38 kinase inhibitors MAPK1, MAPK7, MAP3K1 MAPK14 14/4885BRD4 3203/4885HTR7 2938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.